编者按截至上周五披露的21家医药生物企业在扣除非经常性损益后，除海普瑞 一家外，净利全实现正增长。从目前披露的半年报来看，基金二季度提前布局，“吃药”劲头十足。以下是中国资本证券网整理的二季度基金“吃药”情况，供者参考。
证券代码证券简称基金持股数社保基金持股数七月涨跌幅
300026.SZ红日药业24,402,795.0000－17.4854
300016.SZ北陆药业7,486,686.0000－14.5833
002004.SZ华邦制药19,145,956.00003,157,504.000012.4444
300039.SZ上海凯宝14,214,821.0000－12.1076
600436.SH片仔癀6,471,910.00003,806,002.000011.9354
000566.SZ海南海药58,521,455.0000－8.1293
600332.SH广州药业1,414,219.0000－6.8063
600196.SH复星医药49,584,915.000013,189,126.00006.2076
000919.SZ金陵药业19,192,517.000023,109,247.00006.1478
600535.SH天士力72,988,316.0000－4.9863
000522.SZ白云山A12,539,398.0000－4.2281
000989.SZ九芝堂24,077,064.0000－3.7037
002390.SZ信邦制药479,902.0000－2.1870
600252.SH中恒集团67,526,030.00003,969,295.00002.0073
600557.SH康缘药业64,454,554.0000－1.8268
600867.SH通化东宝16,376,654.0000－1.6688
601607.SH上海医药71,901,228.0000－0.9054
002370.SZ亚太药业337,227.0000－0.6993
300199.SZ翰宇药业5,210,664.00001,358,177.00000.2556
(李正)